CLRB
Price
$3.98
Change
+$0.35 (+9.64%)
Updated
Mar 28, 6:59 PM EST
38 days until earnings call
PDSB
Price
$3.96
Change
+$0.11 (+2.86%)
Updated
Mar 28, 6:59 PM EST
46 days until earnings call
Ad is loading...

CLRB vs PDSB ᐉ Comparison: Which is Better to Invest?

Header iconCLRB vs PDSB Comparison
Open Charts CLRB vs PDSBBanner chart's image
Cellectar Biosciences
Price$3.98
Change+$0.35 (+9.64%)
Volume$1.15M
CapitalizationN/A
PDS Biotechnology
Price$3.96
Change+$0.11 (+2.86%)
Volume$1.49M
CapitalizationN/A
View a ticker or compare two or three
CLRB vs PDSB Comparison Chart

Loading...

CLRBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PDSBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CLRB vs. PDSB commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLRB is a Buy and PDSB is a Buy.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (CLRB: $3.98 vs. PDSB: $3.95)
Brand notoriety: CLRB and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLRB: 151% vs. PDSB: 238%
Market capitalization -- CLRB: $48.91M vs. PDSB: $123.03M
CLRB [@Biotechnology] is valued at $48.91M. PDSB’s [@Biotechnology] market capitalization is $123.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLRB’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • CLRB’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, CLRB is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLRB’s TA Score shows that 5 TA indicator(s) are bullish while PDSB’s TA Score has 5 bullish TA indicator(s).

  • CLRB’s TA Score: 5 bullish, 5 bearish.
  • PDSB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CLRB and PDSB are a good buy in the short-term.

Price Growth

CLRB (@Biotechnology) experienced а +2.84% price change this week, while PDSB (@Biotechnology) price change was -18.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

CLRB is expected to report earnings on May 06, 2024.

PDSB is expected to report earnings on May 14, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CLRB with price predictions.
OPEN
A.I.dvisor published
a Summary for PDSB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
PDSB($123M) has a higher market cap than CLRB($48.9M). CLRB YTD gains are higher at: 43.682 vs. PDSB (-20.423). CLRB has higher annual earnings (EBITDA): -33.67M vs. PDSB (-48.62M). PDSB has more cash in the bank: 54.3M vs. CLRB (19M). CLRB has less debt than PDSB: CLRB (569K) vs PDSB (23.6M). CLRB (0) and PDSB (0) have equivalent revenues.
CLRBPDSBCLRB / PDSB
Capitalization48.9M123M40%
EBITDA-33.67M-48.62M69%
Gain YTD43.682-20.423-214%
P/E RatioN/AN/A-
Revenue00-
Total Cash19M54.3M35%
Total Debt569K23.6M2%
FUNDAMENTALS RATINGS
CLRB vs PDSB: Fundamental Ratings
CLRB
PDSB
OUTLOOK RATING
1..100
7356
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3686
P/E GROWTH RATING
1..100
78100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (49) in the Pharmaceuticals Major industry is in the same range as CLRB (59) in the Biotechnology industry. This means that PDSB’s stock grew similarly to CLRB’s over the last 12 months.

PDSB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CLRB (100) in the Biotechnology industry. This means that PDSB’s stock grew similarly to CLRB’s over the last 12 months.

PDSB's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as CLRB (100) in the Biotechnology industry. This means that PDSB’s stock grew similarly to CLRB’s over the last 12 months.

CLRB's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for PDSB (86) in the Pharmaceuticals Major industry. This means that CLRB’s stock grew somewhat faster than PDSB’s over the last 12 months.

CLRB's P/E Growth Rating (78) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that CLRB’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLRBPDSB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
CLRBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PDSBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BTIRX166.980.19
+0.11%
DWS Equity 500 Index R6
TSYIX11.34N/A
N/A
AMG TimesSquare Global Small Cap I
JHBCX54.70N/A
N/A
JHancock Blue Chip Growth NAV
CIGEX17.36-0.02
-0.12%
Calamos Global Equity I
FOPAX20.15-0.08
-0.40%
Fidelity Advisor Intl Sm Cap Opps A

CLRB and

Correlation & Price change

A.I.dvisor tells us that CLRB and VTGN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRB and VTGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
+9.49%
VTGN - CLRB
33%
Poorly correlated
+15.54%
ORMP - CLRB
31%
Poorly correlated
+3.55%
AXON - CLRB
31%
Poorly correlated
-0.98%
FATE - CLRB
30%
Poorly correlated
N/A
INSM - CLRB
29%
Poorly correlated
-0.70%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+2.73%
AXON - PDSB
43%
Loosely correlated
-0.98%
MDGL - PDSB
38%
Loosely correlated
+3.18%
MNKD - PDSB
37%
Loosely correlated
-2.16%
INZY - PDSB
37%
Loosely correlated
+3.65%
VCYT - PDSB
35%
Loosely correlated
+1.84%
More